Related Experiment Video
Updated: May 3, 2026
07:05
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
5.2K
Pharmacists remuneration models in iran and selected countries: a comparative study.
Amir Hashemi-Meshkini1, Khosro Keshavarz1, Shekoufeh Nikfar2
1Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Pharmaceutical Policy Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iranian Journal of Pharmaceutical Research : IJPR
|February 14, 2014
Summary
Pharmacists
Area of Science:
- Pharmacy practice and healthcare economics.
Background:
- Pharmacists are vital healthcare providers whose services are influenced by remuneration.
- Understanding pharmacy profitability requires examining remuneration models and pricing strategies.
Purpose of the Study:
- To review and compare pharmacist remuneration models and pharmacy profitability factors in Iran, France, Ireland, Canada, and Turkey.
Main Methods:
- A literature review of international data from academic databases (Google, Google Scholar, PubMed, Scopus).
- Collection of domestic data through contact with relevant Iranian organizations.
Main Results:
- Cognitive services for pharmacists are largely uncompensated in Iran and most studied countries, with exceptions in some Canadian provinces.
- Iran's dispensing fee system is inadequate, with limited insurer coverage.
- Iran's pricing methods lead to low prices, negatively impacting pharmacy profitability.
Conclusions:
- Revising the dispensing fee structure in Iran is necessary.
- Implementing a remuneration system for non-owner pharmacists beyond salary is recommended.
- Adopting a new pricing method is crucial for improving pharmacy services and profitability.
Related Concept Videos
01:26Pharmacokinetic Models: Comparison and Selection Criterion
490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
373
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
373
01:20Pharmacokinetic Models: Overview
2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
727
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
727
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
333
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
333
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97